Avalo Therapeutics vs Cardiff Oncology
Cardiff Oncology is the larger business, with $593,000 of revenue in fiscal 2025 against $59,000 for Avalo Therapeutics (10.1 times as much). Cardiff Oncology grew faster (-13.2% against -86.6%). Cardiff Oncology kept more of each dollar of sales as profit: a net margin of -7732.0% against -132642.4%.
| Latest fiscal year | Avalo TherapeuticsAVTX, 2025 | Cardiff OncologyCRDF, 2025 |
|---|---|---|
| Revenue | $59,000 | $593,000 |
| Revenue growth | -86.6% | -13.2% |
| Net income | −$78.3m | −$45.9m |
| Operating margin | -123601.7% | — |
| Net margin | -132642.4% | -7732.0% |
| Return on equity | -72.4% | -71.5% |
| Free cash flow | −$51.5m | −$38.0m |
| Cash | $15.9m | $17.5m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 33 | 31 |
| Market value | $383m | $58.6m |
| Price vs our value range | — | — |
| Moat score | 24 (Weak) | 5 (Weak) |
| Insider trades, 12 months | 0 buys, 43 sales | 4 buys, 0 sales |